Señales en vivo de 4579.T | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 abr 2024 @ 02:15):

Stats
Volumen de hoy	95 100.00
Volumen promedio	124 670
Capitalización de mercado	12.87B
EPS	¥0 ( 2024-02-14 )
Próxima fecha de ganancias	( ¥0 ) 2024-05-12
Last Dividend	¥0 ( N/A )
Next Dividend	¥0 ( N/A )
P/E	-39.69
ATR14	¥0.734 (0.12%)

Volumen Correlación

Largo: -0.01 (neutral)

Corto: -0.62 (weak negative)

Signal:(47.079) Neutral

RaQualia Pharma Inc. Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

RaQualia Pharma Inc. Correlación - Moneda/Commodity

-0.06
( neutral )

0.31
( neutral )

0.35
( neutral )

0.14
( neutral )

-0.14
( neutral )

-0.31
( neutral )

RaQualia Pharma Inc. Finanzas

Annual	2023
Ingresos:	¥1.90B
Beneficio Bruto:	¥1.48B (77.88 %)
EPS:	¥-14.98

FY	2023
Ingresos:	¥1.90B
Beneficio Bruto:	¥1.48B (77.88 %)
EPS:	¥-14.98

FY	2022
Ingresos:	¥2.92B
Beneficio Bruto:	¥2.69B (92.06 %)
EPS:	¥34.50

FY	2021
Ingresos:	¥2.78B
Beneficio Bruto:	¥2.46B (88.45 %)
EPS:	¥7.20

Financial Reports:

No articles found.

RaQualia Pharma Inc.

RaQualia Pharma Inc. engages in the research and development of pharmaceutical compounds worldwide. Its human products portfolio includes tegoprazan for gastroesophageal reflux disease, which is in phase 1 clinical trial in the United States; and grapiprant for pain management, which is in phase II clinical trial in the United States and phase I clinical trial in China, as well as in phase I clinical trial in China and the United States to treat cancer. The company also provides veterinary products such as, grapiprant for osteoarthritis in dogs; ghrelin receptor agonist to treat cancer-related anorexia/cachexia syndrome, and constipation resulting from spinal cord injury; and ELURA, a drug for the management of weight loss in cats with chronic kidney disease. In addition, it provides TRPM8 blocker for the target indication of neuropathic pain; motilin receptor agonist to treat gastrointestinal dysmotility, including gastroparesis, functional dyspepsia, and post-operative ileus; potassium-competitive acid blocker to treat gastro-esophageal reflux disease that has completed phase 1 clinical trial; 5-HT4 partial agonist to treat gastroparesis, functional dyspepsia, and chronic constipation; 5-HT2B antagonist to treat irritable bowel syndrome with diarrhea; EP4 antagonist, a pain management drugs for dogs; serotonin 5-HT2A and dopamine D2 receptor blocker to treat schizophrenia; EP4 antagonist to treat cancer that is in phase I clinical trial, as well as in phase 1 clinical trial for the indication of pain; Cyclooxygenase-2 inhibitor, Phase I clinical trials for the indication of pain; CB2 agonist; selective sodium channel blocker; P2X7 receptor antagonist, which is in Phase I clinical trials for the target indication of neuropathic pain; and retinoic acid receptor alpha agonist. It has a collaborative agreement with Interprotein Corporation, ASKA Pharmaceutical. Co., Ltd., and Epigeneron, Inc. The company was incorporated in 2008 and is headquartered in Nagoya, Japan.